Newsfeed

Lung cancer triggers pulmonary hypertension
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and the German Center for Lung Research found after examining more than 500 patients. The pulmonary hypertension observed is possibly due to immune and inflammatory processes triggered by canc…
Pulmonary Hypertension Association of Canada launches Life in Purple Challenge Campaign for Pulmonary Hypertension Awareness Month
Vancouver, BC (November 7, 2017) ? The Pulmonary Hypertension Association of Canada (PHA Canada) is celebrating Pulmonary Hypertension Awareness Month this November with the launch of the Life in Purple Challenge. This new awareness and fundraising campaign highlights the impacts of pulmonary hypertension (PH) on the everyday lives of patients and caregivers. PH is a rare but very complex and serious lung disease that is progressive and potential…
PHA Fundraising Campaign Asks Canadians to ‘Walk in the Shoes’ of PH Patients
The Pulmonary Hypertension Association of Canada has launched its Life in Purple Challenge campaign to mark November, Pulmonary Hypertension Awareness Month.
PDE5 Blocker May Be an Effective Therapy for Early PH After Heart Attack, Study Suggests
Blocking the enzyme phosphodiesterase 5 (PDE5) is a potential new therapeutic strategy to treat early pulmonary hypertension (PH) in patients who have had a heart attack, a study suggests. The research, “Pulmonary vasodilation by phosphodiesterase 5-inhibition is enhanced and nitric oxide-independent in early pulmonary hypertension after myocardial infarction,” was published in the The American Journal of Physiology-Heart and Circulatory Physi…
New hope for pulmonary hypertension thanks to old drug
Researchers in Alberta may have found a new use for an old generic drug: treating pulmonary arterial hypertension (PAH).
New device helps treat pulmonary hypertension
A new device, the Third Pole is able to generate nitric oxide (NO) from the air that can help improve oxygenation and treat pulmonary hypertension a common problem among some newborns.
Pulmonary Hypertension Association of Canada Holds First Pulmonary Hypertension Eastern Regional Symposium for Patients and Families
The Pulmonary Hypertension Association of Canada will host its first ever Eastern Regional Symposium for patients with pulmonary hypertension (PH) and their families in Toronto on Friday, October 13th and Saturday, October 14th. Over 200 PH patients, caregivers, and healthcare professionals will attend this free networking and educational event. A welcome reception will be held on Friday, October 13th (5 p.m. – 7 p.m.) followed by a full day of p…
Over 2,000 letters being delivered to Premiers and Health Ministers across Canada urging access to life-extending treatment for PAH
Today, Scleroderma Canada and the Pulmonary Hypertension Association of Canada announced that they have collected over 2,000 signed letters and are in the process of delivering them to Premiers and Health Ministers across Canada, including Manitoba, Ontario, Quebec and Nova Scotia. The letters were signed by individuals living with pulmonary arterial hypertension (PAH), their caregivers, family members and friends to urge decision makers to make …
Pulmonary Arterial Hypertension Treatment Gets Expanded FDA Approval
The U.S. Food and Drug Administration (FDA) granted approval to Actelion’s Tracleer (bosentan) tablet for use in pediatric patients ages 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH).
Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for TRACLEER® (bosentan) for use in pediatric patients aged three years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), to improve pulmonary vascular resistance (PVR), which is expected to result in an…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png